Literature DB >> 3804173

Serum concentrations of N-terminal propeptide of type III procollagen and laminin in the outflow of fibrotic livers compared with liver-distal regions.

A M Gressner, W Tittor, A Negwer.   

Abstract

The immunoreactive serum concentrations of the basement membrane glycoprotein laminin, including its split product (pepsin-resistant fragment P1), and of the aminoterminal propeptide of type III procollagen, were measured in liver outflow (hepatic vein) and in liver-distal venous (renal vein) and arterial (femoral artery) regions in liver cirrhotic and fibrotic patients (n = 40). In the majority of patients with liver fibrosis and cirrhosis (0.52 to 0.69) the relatively highest concentrations of laminin (2.09 U/ml, p less than 0.05) and of procollagen propeptide (28.5 ng/ml, p less than 0.001) were found in the hepatic vein. No significant correlations were observed between the concentrations of the two biomatrix proteins in either region of the circulation, but a highly positive statistical correlation (r = 0.9425) was found between the level of laminin in the hepatic vein of cirrhotic subjects and portal venous pressure. The respective correlations were lower for laminin measured in the renal vein and the femoral artery. The concentration of procollagen propeptide was statistically not related to the portal venous pressure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3804173

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  3 in total

1.  Serum type IV collagen in various liver diseases in comparison with serum 7S collagen, laminin, and type III procollagen peptide.

Authors:  C Hirayama; H Suzuki; A Takada; K Fujisawa; K Tanikawa; S Igarashi
Journal:  J Gastroenterol       Date:  1996-04       Impact factor: 7.527

2.  Serum concentrations of laminin in cirrhosis of the liver.

Authors:  J Collazos; F Díaz; J Genollá
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

Review 3.  Is there a place for serum laminin determination in patients with liver disease and cancer?

Authors:  Heitor Rosa; Edison Roberto Parise
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.